Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases.

[1]  N. Alkhouri,et al.  Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience , 2017, Transplantation.

[2]  S. Saab,et al.  Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis , 2017, Journal of clinical gastroenterology.

[3]  Y. Maehara,et al.  Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience , 2017, Journal of Gastroenterology.

[4]  M. Buti,et al.  Management of direct antiviral agent failures , 2016, Clinical and molecular hepatology.

[5]  A. Lok,et al.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. , 2016, Gastroenterology.

[6]  B. Bacon,et al.  Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study , 2016, Hepatology.

[7]  T. Ayer,et al.  Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals , 2016, Hepatology.

[8]  P. Belperio,et al.  Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients , 2016, Hepatology.

[9]  Jean-Michel Pawlotsky,et al.  Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.

[10]  E. Schiff,et al.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence , 2016, Hepatology.

[11]  M. Manns,et al.  Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Christoph Sarrazin,et al.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.

[13]  A. Muir,et al.  Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  G. Cesana,et al.  Cost‐Effectiveness of New Direct‐Acting Antivirals to Prevent Post–Liver Transplant Recurrent Hepatitis , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  P. Kwo,et al.  New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease , 2015, Current opinion in organ transplantation.

[16]  N. Terrault,et al.  Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  X. Forns,et al.  An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.

[18]  Y. Maehara,et al.  Clinical significance of gastrointestinal bleeding after living donor liver transplantation , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  K. Agarwal,et al.  Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity” , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  G. Everson,et al.  Management of the transplant recipient with chronic hepatitis C. , 2013, Clinics in liver disease.

[21]  D. Samuel,et al.  Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. , 2012, Journal of hepatology.

[22]  B. Wall,et al.  Patterns of injury in mycophenolate mofetil-related colitis. , 2010, Transplantation proceedings.

[23]  A. Aronsohn,et al.  Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients , 2009, Journal of clinical gastroenterology.

[24]  R. Wiesner,et al.  Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection , 2008, American Journal of Transplantation.

[25]  L. Jeng,et al.  Fatal duodenal hemorrhage complicated after living donor liver transplantation: case report. , 2008, Transplantation proceedings.

[26]  J. Green,et al.  Iron deficiency anaemia guidelines: time for an update? , 2008, Gut.

[27]  J. Parfitt,et al.  Mycophenolate Mofetil-related Gastrointestinal Mucosal Injury: Variable Injury Patterns, Including Graft-versus-Host Disease-like Changes , 2008, The American journal of surgical pathology.

[28]  M. Berenguer.  Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. , 2008, Journal of hepatology.

[29]  J. Poniachik,et al.  Oral ulcers produced by mycophenolate mofetil in two liver transplant patients. , 2007, Transplantation proceedings.

[30]  Robert S. Brown,et al.  Hepatitis C and liver transplantation , 2005, Nature.

[31]  V. Armstrong,et al.  Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea , 2003, Transplantation.

[32]  A. Moya,et al.  Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipients , 2002, Hepatology.

[33]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[34]  T. Starzl,et al.  Gastrointestinal bleeding after liver transplantation. , 1997, Transplantation.

[35]  W. Sluiter,et al.  Prophylaxis with ranitidine against peptic ulcer disease after liver transplantation , 1988, Transplant international : official journal of the European Society for Organ Transplantation.